Surgical management of liver metastasis

2009 ◽  
pp. 317-320
Author(s):  
Abdullah Jibawi ◽  
David Cade

Surgical management of liver metastasis

2018 ◽  
pp. 415-420
Author(s):  
Abdullah Jibawi ◽  
Mohamed Baguneid ◽  
Arnab Bhowmick

The liver is the most common site for metastases. Perioperative investigations are explored and are critical to the decision as to whether liver metastases should be treated with curative intent. Careful preoperative staging and discussion at a multidisciplinary team meeting is standard practice in established units. This chapter examines surgical management options as well as the neoadjuvant therapies. It details a treatment algorithm for synchronous metastatic colon cancer. It explores newer techniques for improving resectability.


2021 ◽  
Vol 30 (1) ◽  
pp. 27-37
Author(s):  
Amir A. Rahnemai-Azar ◽  
Luke V. Selby ◽  
Maryam B. Lustberg ◽  
Timothy M. Pawlik

2020 ◽  
Vol 9 (6) ◽  
pp. 705-716
Author(s):  
Georgios Antonios Margonis ◽  
Martin E. Kreis ◽  
Jaeyun Jane Wang ◽  
Carsten Kamphues ◽  
Christopher L. Wolfgang ◽  
...  

2007 ◽  
Vol 40 (4) ◽  
pp. 478-484 ◽  
Author(s):  
Takaaki Hanyu ◽  
Kyo Ueki ◽  
Ryuji Wakakuwa ◽  
Dai Ishizuka ◽  
Takashi Tada

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 591-591
Author(s):  
Pablo Emilio Serrano Aybar ◽  
Julian Felipe Daza ◽  
Natalie Solis ◽  
Sameer Parpia ◽  
Steven Gallinger ◽  
...  

591 Background: It has been proposed that PET with 18F-fluorodeoxyglucose alone or combined with CT improves detection of extra hepatic disease in the setting of colorectal cancer liver metastasis (CRLM). However, there remains conflicting evidence on the added benefit of PET/PET-CT prior to liver resection, and its effect on long-term survival. Thus, we set out to perform a systematic review of literature and meta-analysis. Methods: From 2000 to April 2017, MEDLINE, EMBASE, and CENTRAL were searched for studies (prospective and retrospective) investigating the preoperative use of PET/PET-CT in the management of patients with CRLM. We excluded studies in which neoadjuvant chemotherapy was given 2 weeks prior to PET/PET-CT. Screening, data abstraction, and quality assessment was performed in duplicate. Primary outcome was overall survival (OS). Secondary outcomes included disease-free survival (DFS), pre-operative change in surgical management, and open-close surgery. Random effect models were used to pool treatment effects. The protocol was published in PROSPERO. Results: Of 4034 articles reviewed, 37 met the inclusion criteria and were analyzed, and 8 compared PET/PET-CT to conventional imaging. All studies included PET (n=18), PET-CT (n=17), or both (n=2). OS for all patients was similar whether or not pre-operative staging included PET/PET-CT (HR 0.94, 95% CI 0.69-1.26). A similar effect was seen in the subgroup of patients who underwent surgery (HR 0.92, 95% CI 0.72-1.17). DFS in patients who underwent surgery was not different either (HR 0.93, 95% CI 0.81-1.08). PET/PET-CT reduced the odds of undergoing an open-close surgery (OR 0.52, 95% CI 0.35-0.76) and changed the surgical management of 23.4% patients (95% CI 19.33-27.47), however heterogeneity (I2=100%). Conclusions: Pre-operative PET/PET-CT may have a meaningful impact on surgical decision making in CRLM, however heterogeneity between studies is high, likely due to different study designs. It may also reduce the rate of open-close surgeries. The addition of PET/PET-CT to routine pre-operative imaging does not improve OS or DFS.


2013 ◽  
Vol 216 (4) ◽  
pp. 707-716 ◽  
Author(s):  
Skye C. Mayo ◽  
Carlo Pulitano ◽  
Hugo Marques ◽  
Jorge Lamelas ◽  
Christopher L. Wolfgang ◽  
...  

2013 ◽  
Vol 201 (4) ◽  
pp. W582-W589 ◽  
Author(s):  
Silanath Peungjesada ◽  
Thomas A. Aloia ◽  
Harmeet Kaur ◽  
Leonardo Marcal ◽  
Haesun Choi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document